With a market capitalization (market cap) of $1.03B — a measure of how much the company is worth — SpyGlass Pharma, Inc. Common Stock ranks #2,481 among the 2,496 companies tracked, and 357th in Healthcare as of October 28, 2026. Shares trade at $30.90, up 3.31% on the day.
of 2,496 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Not in this snapshot
Not in this snapshot
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 26, 2026. Ranking headline cap is the snapshot figure as of October 28, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 26, 2026 | $1B | — | $29.91 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.03B as of October 28, 2026.
SpyGlass Pharma, Inc. Common Stock's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $30.90 as of October 27, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1B on October 26, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 31,911,164 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.21T | +0.22% |
| #20 | Johnson & Johnson JNJ | $646.92B | +0.91% |
| #23 |
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 28, 2026, SpyGlass Pharma, Inc. Common Stock (SGP) is worth $1.03B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, SpyGlass Pharma, Inc. Common Stock’s book equity is about $-98.84M. Market cap is the market value of the outstanding shares. As of October 28, 2026, its market cap is $1.03B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
SpyGlass Pharma, Inc. Common Stock ranks #2,481 among the 2,496 companies tracked on MarketCapLens. In Healthcare it ranks #357 of 358.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Not in this snapshot
Too little price history
Not in this snapshot
FY 2025
| $506.17B |
| -0.10% |
| #32 | UnitedHealth Group Incorporated UNH | $368.36B | -0.08% |
| #34 | Merck & Co., Inc. MRK | $349.89B | +0.86% |
| #44 | Novartis AG NVS | $298.15B | +1.98% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2478 | Hornbeck Offshore Services, Inc. HOS | $1.04B | +1.00% |
| #2479 | Business First Bancshares, Inc. BFST | $1.04B | +0.16% |
| #2480 | MetroCity Bankshares, Inc. MCBS | $1.04B | -1.04% |
| #2482 | Diversified Energy Company PLC DEC | $1.03B | +1.04% |
| #2483 | Arteris, Inc. AIP | $1.03B | +7.77% |
| #2484 | Oaktree Specialty Lending Corporation OCSL | $1.03B | +1.30% |
SpyGlass Pharma, Inc. Common Stock’s ranking market cap of $1.03B comes from the same snapshot as the rest of this site, as of October 28, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 31,911,164. The historical market-cap series last observed $1B on October 26, 2026.
SpyGlass Pharma, Inc. Common Stock (SGP) shares trade at $30.90, up 3.31% on the day, as of October 28, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.